about
Combined oral contraceptives: venous thrombosisCombined oral contraceptives: venous thrombosisFactor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening.Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in FranceHormones and pregnancy: thromboembolic risks for women.Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control studyDeep vein thrombosis in a tetraparesic patient with mental retardation: case report and review of the literature.Oral contraceptive therapy and the surgical management of ENT patients: a review of current clinical practice.New regimens with combined oral contraceptive pills--moving away from traditional 21/7 cycles.Hormone therapies and venous thromboembolism: where are we now?Risk of cardiovascular events with hormonal contraception: insights from the Danish cohort study.Toward a new concept of "natural balance" in oral estroprogestin contraception.Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France.Angiographically verified cerebrovascular disease in young women on oral contraceptives without previous neurological illness.Case reports describing treatments in the emergency medicine literature: missing and misleading information.After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives.Venous thrombosis and oral contraceptives: current status.Thromboembolic disease and present oral contraception.Impact of combined hormonal contraceptives on vessels functionality.Acute confusion and mutism as a presentation of thalamic strokes secondary to deep cerebral venous thrombosis.Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women.Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day.Resistance to activated protein C in healthy women taking oral contraceptives.Endogenous sex hormones and risk of venous thromboembolism in women and men
P2860
Q24198113-92E7B305-9C30-43AB-8BBB-377E9849E668Q24202769-8F6ADBA0-7F49-45BC-AC85-DA6368314773Q34522772-3FAE3945-0F6D-413B-BD07-6B8FD75860EDQ35153912-C3C59BCD-EA5C-4157-8F1F-226EA652617CQ35852845-6EDBE2E8-161E-4146-A40E-3FC4B98901C2Q36199544-3B646F45-1610-4205-BA8E-B2CFEB48E2D9Q36272816-F911E2CF-8CF7-486E-AFF1-5FD3E3FE0072Q37782317-CBD94CBF-75BC-48BB-BAD6-4E21A6CB4FFBQ37810974-B1E41FD7-3921-443C-AE67-2286B0B6800CQ37813184-5290C1D8-3C01-4757-A1F1-C73E5CC4D1F7Q38110189-1024BBCC-8559-4AFF-AF68-54FED4FF25E9Q38127769-0BD885A0-CE55-4320-9115-C7991CBB610BQ40731548-7A0F60BF-CE11-48BC-B8B7-91535DA1D78DQ42230390-9B26B79A-5DF0-4426-9CFA-871DA7003E3BQ42965316-27BE3417-FF46-4B27-8BD5-26184078BAB4Q43171538-72D29465-5778-4522-869A-0B7D894D64E8Q43267080-484AFD70-77AA-4594-94C6-CA4119E0D03BQ44366013-38473498-1472-41D2-81FD-1DA653882430Q47976989-DDBE7A93-68E4-4214-93E0-AA0E3E066119Q48432900-485D145D-6CF7-460E-B87F-3799D2E22D19Q51827826-E391C0F5-F19F-40AA-B62F-537B35A6C022Q53791853-AA091A51-2087-4457-9054-D809173F08EBQ54161216-24835286-0A00-45BE-BF75-3EA5A70B5ED6Q58007543-0FF35A59-667E-4A31-9C4F-7549C3DD8FB2
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im November 1961 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1961
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
PULMONARY EMBOLISM
@en
PULMONARY EMBOLISM
@nl
type
label
PULMONARY EMBOLISM
@en
PULMONARY EMBOLISM
@nl
prefLabel
PULMONARY EMBOLISM
@en
PULMONARY EMBOLISM
@nl
P1433
P1476
PULMONARY EMBOLISM
@en
P2093
J.K. Anand
W.M. Jordan
P304
P356
10.1016/S0140-6736(61)91061-3
P407
P577
1961-11-01T00:00:00Z